Editor’s note: This investigation examines four specific marketing claims made by No7 for its Future Renew range. Readers should know that ‘clinically proven’ carries no fixed regulatory standard in UK advertising — any brand-funded study qualifies. The trial methodology and expert independence questions examined here are what determine whether those claims hold up.
No7 is the flagship skincare brand of Walgreens Boots Alliance, launched in the UK in 1984. It was created as an internal Boots product line; no individual founder is on record. Future Renew, released in April 2023, was described by Boots as the UK’s largest-ever beauty launch. It centres on Pepticology™ — two synthetic peptides developed with the University of Manchester. No7 claims the blend reverses multiple visible signs of skin damage.
No7’s marketing makes four specific assertions for the Future Renew range. Each concerns the same central word: reverse.
The serum product page states that the product is “clinically proven to reverse visible signs of skin damage.” A second claim expands this: the range is “clinically proven to reverse visible signs of skin damage by up to 10 years.” Brand press materials state that “97% of women had a reversal in the appearance of multiple signs of skin damage.” These signs include fine lines, wrinkles, skin tone, dullness, and texture. The Night Serum, launched in April 2025, carries the broadest claim: “clinically proven to reverse visible signs of skin damage in 100% of users.”
All four claims are based on brand-funded clinical trials. The serum claims rely on a single study involving 38 participants — single-blind, with no placebo arm. The Night Serum’s 100% efficacy claim is based on a separate trial of 44 women.
The serum trial was published in the British Journal of Dermatology in February 2024. The 97% figure is accurate and appears in the published data. In the paper, it refers specifically to the firmness parameter — 97% of participants showed improvement in skin firmness. No7’s marketing applies it to “multiple signs of skin damage,” a composite measure covering fine lines, wrinkles, skin tone, dullness, and texture. The paper does not report a 97% composite responder rate; it reports 82% for undereye wrinkles and 71% for crow’s feet. The marketing has merged a single-parameter finding into a multi-sign claim.
Free weekly newsletter
Get every new investigation directly in your inbox.
Science Checks and Brand Checks across the anti-ageing industry — delivered free.
The methodological limitations are not unique to No7. Perry Romanowski, a veteran cosmetic chemist formerly at Alberto Culver, has noted a field-wide problem: “A lot of the studies on peptides take place in an in vitro-controlled lab environment — meaning cell cultures rather than living subjects — not real-world settings.” He was not commenting on Future Renew specifically. The trial’s own authors acknowledged its constraints separately. Co-author Professor Michael Sherratt of the University of Manchester wrote that the in vivo influence — meaning in living skin — of the peptides is “not defined and will require further studies with larger cohorts.” That concession appears in the brand-funded paper itself. The trial was single-blind — meaning the researchers, but not the participants, knew who was receiving treatment — not double-blind. Its comparator was the untreated side of the same face — not a placebo.
The “10 years” claim requires separate scrutiny. The BJD paper reports net grade changes on clinician-assessed wrinkle and firmness scales. No published methodology translating those scale changes into years of apparent age was identified in any independent source. The Boots claims substantiation page describes the basis as “expert grading of appearance of fine lines and wrinkles.” It does not specify how any grade change corresponds to a decade of apparent ageing.
The Night Serum presents a further evidential gap. No7’s April 2025 press release stated the underpinning biopsy study was “due to be published.” As of March 2026, it exists as a bioRxiv preprint — a pre-publication, unreviewed repository. It has not completed peer review.
The Advertising Standards Authority upheld 18 complaints against a Boots Future Renew TV advert in October 2024. The ruling found it “irresponsible and harmful” due to its light-hearted approach to sun protection. The ASA did not assess whether the “clinically proven to reverse” product claim is adequately substantiated. That question has not been adjudicated.
The word ‘reverse’ carries more evidential weight than the published science supports.
No7’s Pepticology science is genuine and peer-reviewed. The investigation finds the evidence credible but insufficient for the claims built on it. The word “reverse” carries more evidential weight than the published science supports. One claim relies on a 38-person single-blind trial. Another lacks a published age-translation methodology. A third was launched based on a study that had not completed peer review.
